LY333531 / Arxxant
Posted by kinasepro on November 13, 2006
Hi Lilly, So are you guys any closer to market with this protein kinase C-beta inhibiting staurosporine analog, Ruboxistaurin, or not?
I see you announced today the ‘results‘ of your diabetic retinopathy phase iii study. The FDA asked for more data back in August, and its still not clear if we’re going to see an approval, a new trial, or a withdrawal.
J Med Chem 1996, 2664
Org lett 2001, 3409